Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncolytics Bio (ONC.TO)

Oncolytics Bio (ONC.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 154,563
  • Shares Outstanding, K 96,602
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,710 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 23.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.15
  • Number of Estimates 1
  • High Estimate -0.15
  • Low Estimate -0.15
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.69 +131.88%
on 06/12/25
1.80 -11.11%
on 07/09/25
+0.84 (+110.53%)
since 06/11/25
3-Month
0.44 +259.55%
on 06/06/25
1.80 -11.11%
on 07/09/25
+0.72 (+81.82%)
since 04/11/25
52-Week
0.44 +259.55%
on 06/06/25
2.08 -23.08%
on 10/07/24
+0.20 (+14.29%)
since 07/11/24

Most Recent Stories

More News
Stocks in play: Oncolytics Biotech Inc

Announced it will host a key opinion leader webinar to discuss pelareorep in metastatic pancreatic ductal ...

ONC.TO : 1.60 (+5.96%)
Next-Gen Cancer Treatments Gain Steam Amid Oncology Industry Shakeups

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer rates are climbing across the U.S., with stark disparities from state to state. Recent CDC data...

ONCY : 1.1800 (+5.83%)
INAB : 2.29 (unch)
ONC.TO : 1.60 (+5.96%)
TNGX : 5.93 (-2.95%)
MBIO : 2.65 (-1.12%)
ELVN : 22.45 (-1.45%)
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

/CNW/ -- USA News Group News Commentary – Cancer rates are rising everywhere, but more dramatically in some places. According to a new analysis of CDC data,...

ONCY : 1.1800 (+5.83%)
CLDI : 0.7600 (-23.85%)
KZIA : 10.80 (+4.25%)
NUVB : 2.20 (-4.76%)
IMRX : 4.42 (+2.08%)
ONC.TO : 1.60 (+5.96%)
KZA.AX : 0.080 (+9.59%)
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, announced that it...

ONCY : 1.1800 (+5.83%)
ONC.TO : 1.60 (+5.96%)
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

/CNW/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation....

ONCY : 1.1800 (+5.83%)
CELC : 13.63 (+0.07%)
EXEL : 44.86 (-0.69%)
CTOR : 2.82 (-13.23%)
ONC.TO : 1.60 (+5.96%)
TOI : 3.13 (+9.06%)
Investors Turn to Cancer Breakthroughs as Federal Funding Faces Deep Cuts

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – With cancer cases rising and treatment costs hitting new highs, the private sector is under growing pressure...

ONCY : 1.1800 (+5.83%)
MGNX : 1.6100 (+1.90%)
AGEN : 7.06 (+19.26%)
TIL : 24.49 (-8.48%)
ONC.TO : 1.60 (+5.96%)
CATX : 3.98 (-3.16%)
Stocks in play: Oncolytics Biotech Inc

Today announced a strategic update highlighting its compelling clinical data from two tumor types and ...

ONC.TO : 1.60 (+5.96%)
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END

ONCY : 1.1800 (+5.83%)
AZN : 71.13 (-0.95%)
ONC.TO : 1.60 (+5.96%)
VSTM : 4.68 (-1.16%)
CRDF : 4.07 (-2.16%)
MBIO : 2.65 (-1.12%)
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

ONCY : 1.1800 (+5.83%)
AZN : 71.13 (-0.95%)
ONC.TO : 1.60 (+5.96%)
VSTM : 4.68 (-1.16%)
CRDF : 4.07 (-2.16%)
MBIO : 2.65 (-1.12%)
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark   Consistent survival...

ONCY : 1.1800 (+5.83%)
ONC.TO : 1.60 (+5.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the...

See More

Key Turning Points

3rd Resistance Point 1.84
2nd Resistance Point 1.73
1st Resistance Point 1.66
Last Price 1.60
1st Support Level 1.48
2nd Support Level 1.37
3rd Support Level 1.30

See More

52-Week High 2.08
Last Price 1.60
Fibonacci 61.8% 1.46
Fibonacci 50% 1.26
Fibonacci 38.2% 1.07
52-Week Low 0.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar